NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Pulse Biosciences, Inc. (PLSE) Stock Analysis

Pulse Biosciences, Inc. (PLSE) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

PLSE

$53.24

−$1.47 (−2.69%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLSE with… →

PLSE Key Statistics

As of Sep 4, 2026
Trading
Open
$53.68
Previous Close
$54.71
Day's Range
52.75–54.75
52-Week Range
12.56–55.37
Volume
515.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.63
Valuation
Market Cap
$3.80B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3204.40
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.17
Financials (FY)
Revenue (FY)
$350.00K
Net Income (FY)
−$72.78M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
71.32M
1-Year Return
+250.96%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
412.97K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PLSE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+287.76%
2025−21.14%
2024+42.24%
2023+341.88%
2022−81.30%
2021−37.93%
2020+77.93%
2019+17.02%
2018−51.44%
2017+263.08%
2016 (partial year)+42.86%

As of September 4, 2026.

PLSE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$350.00K−$72.78M−20794.6%
2024$0.00−$53.59M—
2023$0.00−$42.21M—
2022$700.00K−$58.51M−8357.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$350.00K−$189.00K−$76.94M−$72.78M−20794.6%
2024$0.00$0.00−$56.26M−$53.59M—
2023$0.00$0.00−$43.57M−$42.21M—
2022$700.00K−$11.24M−$58.06M−$58.51M−8357.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PLSE Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricPLSEMedical Instruments & Supplies medianvs median
Profit margin0.00%0.85%0.8 pts below

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pulse Biosciences, Inc. (PLSE) carries a market capitalisation of $3.80B. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 116.

PLSE last closed at $53.24 on September 4, 2026. That is −$1.47 (−2.69%) against the previous close. Over the past 52 weeks the price has ranged from $12.56 to $55.37. The latest close sits 323.89% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $350.00K. The same year closed with a net loss of $72.78M. The reported profit margin is 0%. That is 0.8 percentage points below the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to −1.17.

Across the 4 fiscal years on file, revenue moves from $700.00K in 2022 to $350.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 3,204.4. On price-to-sales that is 1,010 times the Medical Instruments & Supplies median of 3.17. 55 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +250.96%. Measured over 10 years, that is +26.69% a year compounded. The reported beta is 1.63. Annualized volatility over the trailing 10 years is 92.16%.

Growth & Income

The record shows no dividend for PLSE.

The strongest complete calendar year on file is 2023 at +341.88%; the weakest is 2022 at −81.30%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is +287.76%.

Peer Comparison

Pulse Biosciences, Inc. (PLSE) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pulse Biosciences, Inc. PLSE $3.80B —
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Pulse Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Visit website →